ToolGen Incorporated

A199800

KR7199800004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
67,100 ^KRW	-0.59%		+9.82%	-4.42%

2023	ToolGen Incorporated announced that it has received KRW 33 billion in funding	CI
2023	ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	CI

ToolGen Incorporated has filed an IPO.

September 14, 2021 at 12:00 am EDT

ToolGen Incorporated has filed an IPO.

Security Name: Shares
Security Type: Common Stock
PriceRange: KRW 100000 to KRW 120000

Transaction Features: ESOP Related Offering

Latest news about ToolGen Incorporated

ToolGen Incorporated announced that it has received KRW 33 billion in funding	Nov. 01	CI
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding	23-10-30	CI
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques	23-04-18	CI
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index	22-09-19	CI
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc	22-06-15	CI
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion.	21-12-06	CI
ToolGen Incorporated has filed an IPO.	21-09-14	CI
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc.	20-12-20	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc.	20-12-10	CI
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated.	19-08-19	CI
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion.	19-06-18	CI
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells	18-05-17	CI
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers	17-08-18	CI
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing	17-02-22	CI
ToolGen Incorporated announced that it has received KRW 10.0223744 billion in funding	16-10-13	CI
ToolGen Incorporated announced that it expects to receive KRW 10.0223744 billion in funding	16-10-12	CI
Jong-Moon Kim acquired an additional unknown stake in ToolGen Incorporated from Seong-Hak Choi for KRW 2.7 billion.	16-02-11	CI
ToolGen, Inc. Signs License Agreement with Thermo Fisher Scientific	15-03-11	CI
ToolGen Incorporated announced that it has received KRW 2 billion in funding.	14-10-10	CI
ToolGen Incorporated announced that it expects to receive KRW 2 billion in funding.	14-10-07	CI

ToolGen, Inc. is principally engaged in the development of engineered nucleases. The Companyâs main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TOOLGEN INCORPORATED	-4.42%	386M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B